MX9800555A - Variantes de la proteina p53 y utilizaciones terapeuticas. - Google Patents
Variantes de la proteina p53 y utilizaciones terapeuticas.Info
- Publication number
- MX9800555A MX9800555A MX9800555A MX9800555A MX9800555A MX 9800555 A MX9800555 A MX 9800555A MX 9800555 A MX9800555 A MX 9800555A MX 9800555 A MX9800555 A MX 9800555A MX 9800555 A MX9800555 A MX 9800555A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutical uses
- disclosed
- protein variants
- enhanced
- therapeutical
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108700025695 Suppressor Genes Proteins 0.000 abstract 1
- 238000003782 apoptosis assay Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000005522 programmed cell death Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invencion se refiere a las proteínas derivadas del producto del gen supresor de tumores p53, que posee funciones mejoradas en vista de una utilizacion terapéutica. Se refiere ventajosamente a las proteínas que poseen funciones de supresion de tumores e induccion de muerte celular programada mejoradas, más particularmente en el contexto patologico de proliferacion en los cuales la proteína p53 de tipo silvestre es inactiva. Se refiere igualmente a los ácidos nucleico que codifican para esas moléculas, los vectores que las contienen y su utilizaciones terapéuticas, entre otras en terapia génica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9508729A FR2736915B1 (fr) | 1995-07-19 | 1995-07-19 | Variants de la proteine p53 et utilisations therapeutiques |
PCT/FR1996/001111 WO1997004092A1 (fr) | 1995-07-19 | 1996-07-17 | Variants de la proteine p53 et utilisations therapeutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9800555A true MX9800555A (es) | 1998-04-30 |
Family
ID=9481133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9800555A MX9800555A (es) | 1995-07-19 | 1996-07-17 | Variantes de la proteina p53 y utilizaciones terapeuticas. |
Country Status (22)
Country | Link |
---|---|
US (2) | US6326464B1 (es) |
EP (1) | EP0839194B1 (es) |
JP (1) | JPH11510378A (es) |
KR (1) | KR100501881B1 (es) |
AT (1) | ATE324442T1 (es) |
AU (1) | AU725841B2 (es) |
BR (1) | BR9611087A (es) |
CA (1) | CA2224468C (es) |
CZ (1) | CZ296185B6 (es) |
DE (1) | DE69636072T2 (es) |
DK (1) | DK0839194T3 (es) |
ES (1) | ES2263161T3 (es) |
FR (1) | FR2736915B1 (es) |
HU (1) | HU225937B1 (es) |
IL (1) | IL122991A (es) |
MX (1) | MX9800555A (es) |
NO (1) | NO322477B1 (es) |
PT (1) | PT839194E (es) |
SK (1) | SK286955B6 (es) |
TW (1) | TW444022B (es) |
WO (1) | WO1997004092A1 (es) |
ZA (1) | ZA966127B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11510386A (ja) | 1995-07-28 | 1999-09-14 | マリー キュリー キャンサー ケア | 輸送蛋白質およびそれらの使用 |
US6881571B1 (en) | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
FR2775984B1 (fr) * | 1998-03-11 | 2006-09-15 | Bioscreen Therapeutics Sa | Criblage differentiel qualitatif |
FR2755144B1 (fr) * | 1996-10-29 | 1998-11-27 | Rhone Poulenc Rorer Sa | Fragments d'anticorps a chaine unique anti-p53 et utilisation |
US6017735A (en) * | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
US5943914A (en) * | 1997-03-27 | 1999-08-31 | Sandia Corporation | Master-slave micromanipulator apparatus |
PL336523A1 (en) | 1997-04-28 | 2000-07-03 | Rhone Poulenc Rorer Sa | Intraneoplastic delivery of an angiogenesis antagonist by means of adenoviruses in order to treat neoplasms |
IL121041A0 (en) * | 1997-06-09 | 1997-11-20 | Yeda Res & Dev | Immunogenic compositions for induction of anti-tumor immunity |
DE19751587A1 (de) | 1997-11-21 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Onkogen- oder virusgesteuerte Expressionssysteme |
CA2354862A1 (en) * | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
US6831155B2 (en) * | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
US7196242B2 (en) * | 2000-05-16 | 2007-03-27 | The Regents Of The University Of California | Methods for identifying novel therapeutics and diagnostics in the p53 pathway |
US7534861B2 (en) * | 2003-01-10 | 2009-05-19 | Ambergen, Inc. | Compositions and methods for immunoaffinity purification |
WO2005074521A2 (en) * | 2004-01-30 | 2005-08-18 | The Trustees Of Columbia University In The City Of New York | C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF |
US20060246143A1 (en) * | 2005-04-28 | 2006-11-02 | Hilmi Ege | Targeted therapy via targeted delivery of energy susceptible nanoscale magnetic particles |
KR100749858B1 (ko) | 2005-08-12 | 2007-08-16 | 연세대학교 산학협력단 | p53 변이체 및 그의 용도 |
US9539327B2 (en) * | 2007-11-26 | 2017-01-10 | The Research Foundation For The State University Of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
US9186317B2 (en) * | 2007-11-26 | 2015-11-17 | Stc.Unm | Active nanoparticles and method of using |
KR102092345B1 (ko) | 2013-09-30 | 2020-03-24 | 삼성전자주식회사 | 류신 지퍼 변이체 및 이의 용도 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0598806A1 (en) * | 1991-08-09 | 1994-06-01 | E.I. Du Pont De Nemours And Company | Synthetic storage proteins with defined structure containing programmable levels of essential amino acids for improvement of the nutritional value of plants |
GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
FR2710846B1 (fr) * | 1993-10-04 | 1995-12-22 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives. |
US5700657A (en) * | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
WO1995017213A1 (en) * | 1993-12-21 | 1995-06-29 | Sloan-Kettering Institute For Cancer Research | P53-based polypeptide fragments, nucleic acid molecules encoding same, and uses thereof |
US5573925A (en) * | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
EP0799243A4 (en) | 1994-11-28 | 1998-08-19 | Wistar Inst | p53 PROTEINS WITH CHANGED TETRAMERIZATION DOMAINS |
-
1995
- 1995-07-19 FR FR9508729A patent/FR2736915B1/fr not_active Expired - Fee Related
-
1996
- 1996-07-17 BR BR9611087A patent/BR9611087A/pt not_active Application Discontinuation
- 1996-07-17 CZ CZ0014498A patent/CZ296185B6/cs not_active IP Right Cessation
- 1996-07-17 DK DK96925799T patent/DK0839194T3/da active
- 1996-07-17 ES ES96925799T patent/ES2263161T3/es not_active Expired - Lifetime
- 1996-07-17 MX MX9800555A patent/MX9800555A/es not_active IP Right Cessation
- 1996-07-17 KR KR10-1998-0700392A patent/KR100501881B1/ko not_active IP Right Cessation
- 1996-07-17 JP JP9506356A patent/JPH11510378A/ja not_active Ceased
- 1996-07-17 AU AU66186/96A patent/AU725841B2/en not_active Ceased
- 1996-07-17 CA CA2224468A patent/CA2224468C/fr not_active Expired - Fee Related
- 1996-07-17 HU HU9901343A patent/HU225937B1/hu not_active IP Right Cessation
- 1996-07-17 SK SK63-98A patent/SK286955B6/sk not_active IP Right Cessation
- 1996-07-17 PT PT96925799T patent/PT839194E/pt unknown
- 1996-07-17 US US08/983,035 patent/US6326464B1/en not_active Expired - Fee Related
- 1996-07-17 IL IL122991A patent/IL122991A/en not_active IP Right Cessation
- 1996-07-17 EP EP96925799A patent/EP0839194B1/fr not_active Expired - Lifetime
- 1996-07-17 AT AT96925799T patent/ATE324442T1/de active
- 1996-07-17 DE DE69636072T patent/DE69636072T2/de not_active Expired - Lifetime
- 1996-07-17 WO PCT/FR1996/001111 patent/WO1997004092A1/fr active IP Right Grant
- 1996-07-18 ZA ZA9606127A patent/ZA966127B/xx unknown
- 1996-07-19 TW TW085108831A patent/TW444022B/zh not_active IP Right Cessation
-
1998
- 1998-01-16 NO NO19980203A patent/NO322477B1/no not_active IP Right Cessation
-
2001
- 2001-10-03 US US09/968,851 patent/US6933373B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9800555A (es) | Variantes de la proteina p53 y utilizaciones terapeuticas. | |
KR960700752A (ko) | 광범위한 종양억제 유전자와 유전자 생성물 그리고 종양억제 유전자 요법의 방법 | |
EP0804609A4 (en) | NEW GENES OF RESPONSE p53 | |
ES8500322A1 (es) | Un metodo de modificar un virus para conferirle una nueva funcion biologica. | |
AU7079396A (en) | Anti-galalpha(1,3)gal antibody binding peptides | |
EP1312679B8 (en) | Recombinant MVA virus, and the use thereof | |
BG100771A (en) | Hematopoeic protein and ways and methods for its preparation | |
NZ292565A (en) | Production of stabilised complement protein-3 convertase | |
EP1012603A4 (en) | FUNCTIONAL FRAGMENTS OF THE HIV-1 VPR PROTEIN AND METHODS OF USE | |
AU6282896A (en) | Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins | |
FR2744455B1 (fr) | Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications | |
ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
FI964186A (fi) | Ei-liittävät gp350/220-variantit | |
AU2001280639A1 (en) | 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor | |
DE69936513D1 (de) | Menschliche p51-gene und deren genprodukte | |
AU2002352068A1 (en) | 2150, a human protein kinase family member and uses therefor | |
AU2002359572A1 (en) | 15603, a human ion channel family member | |
AU2001257405A1 (en) | 14911 novel protein kinase molecules and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HC | Change of company name or juridical status |
Owner name: MEDIMMUNE LIMITED |
|
MM | Annulment or lapse due to non-payment of fees |